Pre-order Enquiry
Request Free Sample
Global Deflazacort Market Insights, Forecast to 2028
SKU ID : QYR-20154868 | Publishing Date : 08-Feb-2022 | No. of pages : 114
Request Sample
Request Customization
Check Discounts
Deflazacort (trade name Calcort among others) is a glucocorticoid used as an anti-inflammatory and immunosuppressant.
Market Analysis and Insights: Global Deflazacort Market
Due to the COVID-19 pandemic, the global Deflazacort market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Suspension accounting for % of the Deflazacort global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Deflazacort market size is valued at US$ million in 2021, while the US and Europe Deflazacort are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Deflazacort landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Deflazacort include Sanofi, Novartis, Leti, Teva, Nidda Healthcare, Zubit Life Care, Sanify Healthcare, Alna and Royal Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Deflazacort Scope and Segment
Deflazacort market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Deflazacort market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Suspension
Tablet
Segment by Application
Hospital
Drug Store
By Company
Sanofi
Novartis
Leti
Teva
Nidda Healthcare
Zubit Life Care
Sanify Healthcare
Alna
Royal Pharma
Kemofarmacija
Galenpharma
Hanlim Pharma
Kern Pharma
Laboratorios Normon
Tarbis
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Market Analysis and Insights: Global Deflazacort Market
Due to the COVID-19 pandemic, the global Deflazacort market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Suspension accounting for % of the Deflazacort global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Deflazacort market size is valued at US$ million in 2021, while the US and Europe Deflazacort are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Deflazacort landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Deflazacort include Sanofi, Novartis, Leti, Teva, Nidda Healthcare, Zubit Life Care, Sanify Healthcare, Alna and Royal Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Deflazacort Scope and Segment
Deflazacort market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Deflazacort market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Suspension
Tablet
Segment by Application
Hospital
Drug Store
By Company
Sanofi
Novartis
Leti
Teva
Nidda Healthcare
Zubit Life Care
Sanify Healthcare
Alna
Royal Pharma
Kemofarmacija
Galenpharma
Hanlim Pharma
Kern Pharma
Laboratorios Normon
Tarbis
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
